Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

PI3K-delta inhibitor XL-499 shows promising preclinical activity

Dec. 2, 2010

Pfizer's phase III axitinib trial in renal cell carcinoma meets primary endpoint

Dec. 1, 2010

Immunovaccine and OncoTherapy Science join to develop cancer vaccine

Dec. 1, 2010

Multikinase inhibitor AI-1008 shows promise to treat chronic myeloid leukemia in preclinical testing

Dec. 1, 2010

GlaxoSmithKline claims new inhibitors of focal adhesion kinase 1

Dec. 1, 2010

Preclinical activity of LY-S6KAKT1 justifies entry into phase I trial as cancer therapy

Dec. 1, 2010

FDA to review Spectrum Pharma's complete response regarding Fusilev sNDA

Nov. 30, 2010

New inhibitors of cell division protein kinase 4 claimed

Nov. 30, 2010

New inhibitors of dual specificity protein kinase TTK patented

Nov. 30, 2010

CXR-1002 shows promising safety and antitumor activity in first-in-human trial in advanced cancer

Nov. 30, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...